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Abstract Prenatal heart disease spans the spectrum of
severity from very mild to severe life-threatening condi-
tions. An accepted scale for grading fetal cardiovascular
disease severity would aid in anomaly standardization,
counseling, and future research. The Fetal Cardiovascular
Disease Severity Scale with seven severity grades ranging
from mild (grade 1) to severe (grade 7) disease was
developed. Severity grade relates to the cardiovascular
condition diagnosed by fetal echocardiography, with fac-
tors including postnatal intervention, number of interven-
tions anticipated, likelihood of two-ventricle repair versus
single-ventricle palliation, and overall prognosis. A survey
describing 25 cardiac anomalies was offered to fetal
cardiologists at six institutions for validation of scale
reliability among practitioners. The study participants
graded defects using this scale. A smaller group graded
anomalies again more than 2 weeks after the initial survey.
The intraclass correlation coefficient (ICC) was used to
assess agreement of the respondents. The survey partici-
pants were 14 experienced fetal cardiologists: 9 from the
Children’s Hospital of Philadelphia (CHOP) and 5 from
five additional institutions in the United States. The initial
survey ICC was high [0.93; 95 % confidence interval (CI)
0.88–0.96]. The subanalysis showed a higher ICC for the
participants outside CHOP (0.95; 95 % CI 0.91–0.98 vs.
0.92; 95 % CI 0.86–0.96, respectively). The ICCs were
high for all the fetal cardiologists participating in the repeat
evaluation, ranging from 0.92 to 0.99 (95 % CI 0.65–1.00).
The Fetal Cardiovascular Disease Severity Scale demon-
strated good inter- and intrarater reliability among experi-
enced fetal cardiologists and is a valid tool for
standardization of prenatal cardiac diagnostic assessment
across institutions. The scale has applications for parental
counseling and research in fetal cardiovascular disease.
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Introduction
Judgment of the severity of a particular form of congenital
heart disease (CHD) comprises a multitude of factors
including the anatomy and pathophysiology of the lesion as
well as the number and type of interventions available to treat
or palliate the condition. The outcomes and overall quality of
life created through surgical and medical management, both
short and long term, also are factors that enter into consid-
eration of severity [1, 9, 10].
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With the advent of fetal echocardiography, diagnosis of
CHD before birth currently is well established [4, 5]. Early
diagnosis enables a smooth transition from pre- to postnatal
life and improves infant survival and morbidity [2, 7, 11].
The anatomy of the lesion, its implications for delivery,
expected neonatal and life-long interventions, and overall
prognosis all are discussed currently with families before
the birth of a baby with CHD [8].
To provide accurate estimates of the clinical course of
CHD based on fetal imaging alone, prenatal cardiac care
providers, including pediatric cardiologists, maternal fetal
medicine specialists, genetic counselors, and nurses, must
convey an overall assessment of the lesion severity to
families during counseling and to the medical team caring
for the baby during delivery and after birth.
A comprehensive, standardized, and validated system to
rate the severity of CHD in the fetus would be of great
value to patients, their families, and the medical commu-
nity caring for them. A uniform measure of disease severity
could improve communication and conveyance of infor-
mation at prenatal counseling. It also would aid in research
studies assessing outcomes, particularly across institutions.
This study aimed to introduce such a tool, the Fetal
Cardiovascular Disease Severity Scale, and to describe its
validation across different centers.
Methods
Design of the Scale
Experts in the field of fetal and pediatric cardiology devel-
oped the Fetal Cardiovascular Disease Severity Scale to
grade the severity of CHD (Table 1). In designing this scale,
the experts carefully considered those elements that come
into play in the attempt to describe the severity of a particular
form of CHD at the time of fetal diagnosis and counseling.
To provide adequate gradation of each lesion with its own
unique constellation of features, seven levels of severity
were included in the scale. It then was sent for evaluation and
review to the group of cardiologists, who further modified
and revised it based on their feedback until a consensus was
reached as to the content and design of the scale.
The degree of severity in the scale is determined by ele-
ments including the general category of anatomic com-
plexity of heart disease (e.g., isolated valve pathology vs.
isolated septal defect vs. complex outflow tract abnormality
vs. ventricular hypoplasia), the need for postnatal interven-
tion and its complexity, the number of lifelong interventions
(catheter based or operative) anticipated, the likelihood that
an intervention will lead to a two-ventricle repair versus
single-ventricle palliation, and the overall prognosis with
regard to quality and duration of life.
Table 1 describes the seven levels of severity ranging
from level 1 (least severe) to level 7 (most severe). Each
level is structured by a definition concerning anatomic
categorization, the treatment anticipated, and the prognosis
or anticipated outcome. A brief summary term describing
each level is listed. Subjects with a possible two-ventricle
management strategy can be graded at levels 1–7, whereas
those with a single ventricle are graded only at levels 5–7.
Genetic/chromosomal abnormalities and extracardiac
anomalies are not included in the scale because they may
independently affect the prognosis irrespective of the cardiac
condition. They are therefore considered additive to the
cardiovascular severity. In addition, the Fetal Cardiovascu-
lar Disease Severity Scale is designed to grade the severity of
structural CHD. Cardiomyopathies and arrhythmias are
excluded because they have their own unique considerations
and features that influence severity and because the aim was
to create a more streamlined assessment tailored to the gra-
dation of structural cardiac malformations.
Validation of the Scale
This assessment aimed to validate the Fetal Cardiovascular
Disease Severity Scale and to determine its use among fetal
cardiologists. Validity was determined by the degree of
agreement among experienced fetal cardiologists in grad-
ing a sample of cases.
A survey was administered to fetal cardiologists within
our institution, the Children’s Hospital of Philadelphia
(CHOP), and to experienced fetal cardiologists at other
institutions across the United States. Input provided by fetal
cardiologists from multiple different centers introduced
different institutional experiences, regional biases, and local
outcomes to this analysis. The participating centers included
the Children’s National Medical Center (MTD, Washington
DC, USA), the University of California–San Francisco
(AMG; San Francisco, CA, USA), the CS Mott Children’s
Hospital at the University of Michigan (CGF; Ann Arbor,
MI, USA); and the Advocate Children’s Hospital (BC; Oak
Lawn, IL, USA). One of the fetal cardiologists at CHOP
(C.B.F.), who had recently arrived from another institution
[Texas Children’s Hospital (TCH)], was therefore consid-
ered to offer judgments that reflected her experiences in fetal
cardiac care at TCH and not CHOP.
The survey assessment was sent via email to all the
study participants. The survey consisted of 25 hypothetical
case examples covering a wide spectrum of cardiovascular
conditions diagnosed in fetal life by echocardiography
(Table 2). The participants were asked to grade each of the
lesions using the scale configured in Table 1. The respon-
ses then were emailed back to CHOP for compilation of
data. The fetal cardiologists were blinded to the answers of
the other participants.
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Data Analysis
The intraclass correlation coefficient (ICC) was used to
assess agreement between respondents to determine inter-
rater reliability. The minimum, maximum, range, standard
deviation, and interquartile ranges of the case severity
grades from the respondents also were computed. Next, the
25 cases on the worksheet were shuffled to change their
order and then sent to a smaller subgroup of the initial
participants, including all nine CHOP fetal cardiologists
and one outside fetal cardiologist. These participants,
blinded to their previous answers, were again asked to
grade the diagnoses using the severity scale. The ICC
comparing the answers of the individual respondent with
the same diagnosis at different points in time was used to
assess for agreement and to determine the intrarater reli-
ability of the scale.
Results
The participants in the survey evaluation were 14 physi-
cians: 9 fetal cardiologists trained in fetal cardiology and/or
practicing it at the Fetal Heart Program at CHOP and 5 fetal
cardiologists trained in fetal cardiology and/or practicing it
at other institutions. Of these 14 participants, 10 evaluated
the severity of the same diagnoses on a shuffled worksheet,
with a minimum of 2 weeks between the completion of the
Table 1 Fetal cardiovascular disease severity scale
Status Definition Treatment Prognosis/anticipated
outcome




with minimal, if any,
negative impact on
well-being
None Excellent/normal quality of
life









Medical management may be
required in utero or after birth.
Surgery or catheter therapy is
possible but will need to await












form of CHD (two-
ventricle)
Surgery or catheter therapy will,













Surgery will, with certainty, be
required. Further additional
interventions or surgery may
be necessary at some point in
life













CHD, single- or two-
ventricle type
Fontan surgical palliation
strategy is required for single-
ventricle patients, or surgery
for two-ventricle repair will,
with certainty, be required,
and further intervention or
surgery will, with certainty, be
necessary in the future
Prognosis is fair to good;
infant is likely to survive
surgery. Quality of life may
be impaired or duration of
life may be limited
Single-ventricle strategy, low
risk; two-ventricle strategy,










CHD, single- or two-
ventricle type
Fontan surgical palliation
strategy is required, but at
high risk, or two-ventricle
repair, but at high risk
Prognosis is poor to fair; risk
of death is possible; and
long-term complications are
highly likely. Survival
beyond childhood is poor.
Single-ventricle strategy, high
risk; two-ventricle strategy








CHD with very poor
prognosis
Intervention may be offered, but
the expected outcome is poor
Fetal or perinatal demise
likely, despite intervention
Poor outcome; survival beyond
early period of life not
expected
4 4
Scale composed of 7 grades, italicized important considerations for an overall assessment of lesion severity
1V single ventricle palliation anticipated, 2V biventricular repair anticipated
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two surveys. The ICC of 0.93 [95 % confidence interval (CI)
0.88–0.96] among all the respondents demonstrated a high
level of agreement between providers. The fetal cardiolo-
gists from outside institutions demonstrated an ICC of 0.95
(95 % CI 0.91–0.98), whereas the ICC for the participants at
CHOP was 0.92 (95 % CI 0.86–0.96).
The range of severity grade responses by case is listed in
Table 3. Overall, 60 % of the cases had respondents who
offered a severity scale grade within one or two severity
levels of each other, and 96 % of the cases had a severity
scale grade within three levels of each other or less. In one
case, the participants demonstrated a severity grade range
of four levels (case 23: critical aortic valve stenosis, normal
size, and functioning left ventricle).
All the cases had an interquartile range within one or
two levels of severity, indicating that responses outside
these levels were outliers (Fig. 1). The ICCs were high for
all the fetal cardiologists participating in the repeat eval-
uation, ranging from 0.92 to 0.99 (95 % CI 0.65–1.00)
(Table 4).
Discussion
Currently, the first point of entry into the realm of con-
genital heart care commonly occurs before birth with a
prenatal diagnosis. Establishment of disease severity
among the myriad of conditions that exist is an essential
aspect of prenatal care for CHD. Disease severity influ-
ences decisions concerning continuation of the pregnancy,
dictates management for the remainder of gestation, and
affects planning for delivery and postnatal care. A com-
monly accepted grading system for fetal cardiovascular
conditions among practitioners would be of great value in
creating a common language, and importantly, could
function as an instrument for investigational studies. A




1 TOF, mild pulmonic stenosis
2 Echo bright spot on left ventricular papillary
muscles, otherwise normal heart structure and
function
3 HLHS, mitral atresia, aortic atresia, open
unrestrictive atrial septum, no tricuspid
regurgitation
4 Midmuscular VSD, small
5 Complete AV canal defect, mild AV valve
regurgitation
6 Left ventricle-to-right ventricle size discrepancy,
left superior vena cava to coronary sinus, mild
aortic arch narrowing
7 Heterotaxy syndrome, single ventricle, pulmonary
atresia, total anomalous pulmonary venous return
(infradiaphragmatic)
8 TGA (intact ventricular septum)
9 Two-vessel umbilical cord, otherwise normal heart
structure and function
10 Double-outlet right ventricle, subaortic VSD with
severe pulmonic stenosis
11 HLHS, mitral stenosis, aortic atresia, intact atrial
septum
12 Floppy, redundant atrial septum and premature
atrial contractions, otherwise normal heart
structure and function
13 TOF with pulmonary atresia, very small hypoplastic
branch pulmonary arteries, and suspicion of
multiple aortopulmonary collaterals
14 Truncus arteriosus (type 2A with VSD and branch
pulmonary arteries arising from side of trunk), no
truncal valve stenosis or regurgitation
15 Large perimembranous VSD
16 Tricuspid atresia, normally related great vessels,
moderate size VSD, moderate pulmonic stenosis
17 Pulmonary atresia with intact ventricular septum,
marked right ventricular hypoplasia, severe
tricuspid valve hypoplasia; inflow into the
ventricle noted, but no tricuspid regurgitation seen
18 Truncus arteriosus (type 1A with VSD and main
pulmonary artery segment giving rise to well-
formed branch pulmonary arteries) abnormal
truncal valve with severe truncal insufficiency
19 TGA, VSD, pulmonic stenosis
20 Ebstein’s anomaly, pulmonary atresia, severe
tricuspid regurgitation, severe hydrops
21 Complete AV canal defect, balanced, no AV valve
regurgitation
22 Interrupted aortic arch type B, VSD, mild subaortic
narrowing






24 Pulmonary atresia with intact ventricular septum,
near normal size tricuspid valve, plate-like
pulmonary atresia, moderate tricuspid
regurgitation
25 Coarctation of the aorta, normal left ventricle
Fetal cardiologists were asked to assess each case and assign a
severity grade from 1 to 7 to the case using the Fetal Cardiovascular
Disease Severity Scale
TOF tetralogy of Fallot, HLHS hypoplastic left heart syndrome, AV
atrioventricular, VSD ventricular septal defect, TGA transposition of
the great arteries
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means of categorizing fetal cardiovascular disease severity,
in essence the diagnosis of CHD at its earliest presentation,
also could serve as a tool for gauging resource use and cost
effectiveness. In this report, we describe the development
of such a tool and its validation.
Methods for categorizing the clinical variability in
congenital heart anomalies currently exist, but none are
specifically designed for prenatal use. Task Force One of
the 32nd Bethesda Conference of the American College of
Cardiology uses elements of both anatomic diagnosis and
surgical repair to divide adult patients with congenital heart
defects into three groups of severity [12]: simple CHD,
CHD of moderate severity, and CHD of great complexity,
also described as simple, moderate, and severe CHD.
The Aristotle Score for Congenital Heart Surgery is
designed to rate the complexity of surgical procedures used
in palliating CHD based on morbidity, mortality, and
anticipated level of surgical difficulty [6]. Patient
characteristics also are taken into consideration with this
system to provide a comprehensive score.
A consensus-based method of risk adjustment for in-
hospital mortality after surgery to repair CHD is called the
Risk Adjustment for Congenital Heart Surgery (RACHS-1)
[3]. This system is designed to assess perioperative surgical
mortality for children with CHD who are 18 years old or
younger and allows for meaningful comparisons of surgical
outcomes across institutions.
The aforementioned scoring systems do not provide a
framework for a comprehensive assessment of CHD severity
Table 3 Initial survey results of severity level assessment by case
Case no. Case severity level
min–max (range)
SD
1 3–4 (2) ±0.4
2 1 (1) ±0
3 5–6 (2) ±0.5
4 1–2 (2) ±0.5
5 3–5 (3) ±0.6
6 1–3 (3) ±0.4
7 5–7 (3) ±0.6
8 3–5 (3) ±0.5
9 1 (1) ±0
10 3–5 (3) ±0.6
11 6–7 (2) ±0.5
12 1–2 (2) ±0.4
13 5–6 (2) ±0.5
14 4–5 (2) ±0.5
15 2–3 (2) ±0.4
16 5 (1) ±0
17 5–6 (2) ±0.5
18 5–7 (3) ±0.6
19 4–6 (3) ±0.6
20 7 (1) ±0
21 3–5 (3) ±0.6
22 4–5 (2) ±0.5
23 3–6 (4) ±0.7
24 3–5 (3) ±0.6
25 3–4 (2) ±0.5
Minimum, maximum, range, and SD of severity grade assignments
are listed by case
Min minimum, max maximum, SD standard deviation
Fig. 1 Boxes and horizontal single lines represent the interquartile
range of responses to assignment of severity level by case, whereas
whiskers and dots represent outlying responses. For example, in case
2, all the participants agreed that the case should be assigned a
severity level of 1, represented by the single line. In case 8, all the
participants within the interquartile range assigned the case a severity
level of 4, again represented by the single line. The dots represent the
outliers who graded the case at a severity level of 3 or 5. Finally, in
case 21, the participants within the interquartile range assigned the
case a severity level of either 3 or 4, represented by the rectangle. An
outlier assigned it a severity level of 5, represented by the whisker.
This figure demonstrates that interquartile ranges for all the cases
were within one or two severity levels, whereas all the outliers were
within one level of the interquartile range
Table 4 Survey results of in-
traobserver reliability assess-
ment by provider
ICCs with 95 % CIs for each
provider were used to assess
intraobserver variability
ICC intraclass correlation coef-
ficient, CI confidence interval
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diagnosed in fetuses during the prenatal period, whereas the
Fetal Cardiovascular Disease Severity Scale is uniquely
designed for this patient population. In addition, these scoring
systems take a more simplified approach to grading a group of
extremely diverse cardiac lesions with unique features that
affect risk and outcome. The 7-point system of the Fetal
Cardiovascular Disease Severity Scale takes into account
features beyond the anatomic complexity of the lesion,
including need and number of interventions, two- versus
single-ventricle palliation, and overall prognosis, making this
scale a more comprehensive assessment of severity.
High ICCs comparing responses of fetal cardiologists
with one another and with themselves indicate that the
Fetal Cardiovascular Disease Severity Scale is a valid
method for assessing structural CHD diagnosed in prenatal
life. Agreement between the participants at CHOP (ICC
0.92) was slightly less than between those at the outside
institutions (ICC 0.95). This may have been due to a higher
number of CHOP participants from CHOP (9 participants)
than from outside institutions (5 participants), leading to
more opportunity for variability in response grades.
The ranges for the responses typically fell between one
and two grades of severity, with some cases involving three
grades, although the interquartile ranges all were within
one or two levels. The sole case with a range of four
severity grades had ‘‘critical aortic valve stenosis, normal
size, and functioning left ventricle.’’ Of the 14 respondents,
12 identified this diagnosis as falling within severity grade
level 4 or 5. One respondent graded the severity in this case
as level 3, whereas one other respondent graded it as level
6. However, during the second evaluation to assess in-
trarater reliability, both respondents, blinded to their pre-
vious answers, independently graded the severity of the
same diagnosis as level 4.
The description of critical aortic valve stenosis provided
to the participants did not identify the gestational age of the
fetus. This could have influenced the grade assignment
because critical aortic stenosis with normal left ventricular
function in a fetus at 20 weeks could potentially progress
in utero, leading to a newborn with poor ventricular
function or raising concern about the development of
hypoplastic left heart syndrome. Such a diagnosis made at
36 weeks gestation would be less likely to create uncer-
tainty about progression of the disease.
Certain conditions, such as the aforementioned case of
critical aortic stenosis, can evolve anatomically during
gestation. In other cases, the anatomy can lead to hemo-
dynamic compromise, as in dysplastic tricuspid valve with
tricuspid valve regurgitation, in which the degree of
regurgitation worsens during gestation, causing hydrops
and affecting prognosis.
The grading system used in the Fetal Cardiovascular
Disease Severity Scale can be applied to each individual at
multiple points in gestation as the fetal cardiovascular
disease evolves. This can provide families with a more
concrete parameter for understanding the implication of
these changes during gestation. In addition, it can give fetal
cardiologists a way to communicate the fetal cardiovas-
cular disease course during gestation effectively to obste-
tricians and postnatal cardiologists.
In general, variability in responses across participants
may be influenced by either institutional or personal
experience with a specific individual defect. Furthermore,
particular conditions in fetal life may be difficult to grade
because they are plagued by uncertainty in outcomes based
on a particular strategy, such as the notion that the outcome
of a ‘‘good’’ single-ventricle strategy may be superior to
that of a ‘‘poor’’ two-ventricle repair strategy. Neverthe-
less, our analysis showed that for a large heterogeneous
group of 25 anomalies, the Fetal Cardiovascular Disease
Severity Scale demonstrated excellent interclass correla-
tion and hence can be used between practitioners and
across institutions.
This assessment had several limitations. The survey was
a subjective evaluation by a limited number of attending
fetal cardiologists with variable years of practitioner
training and experience. It did not include the gestational
age of the fetuses, which could have influenced the grade
assignment. Responses could have varied due to recall bias
of the most recent or more memorable cases. The scale was
assessed by fetal cardiologists and has not been validated
among maternal-fetal medicine specialists or other practi-
tioners who may care for patients with prenatal CHD. In
addition, the scale did not take into account genetic
information or the presence of other extracardiac anomalies
that could independently affect long-term outcome and
prognosis.
Finally, the scale was designed for a general global
assessment of CHD severity. Therefore, factors that con-
tribute to severity (e.g., the number of interventions
anticipated and overall prognosis) are paired within the
scale. It is possible that for some conditions, the number of
interventions or the complexity of the intervention and
prognosis may be disparate. Hence, a particular diagnosis
may not fit precisely within one level, which may con-
tribute to variability in grades.
The Fetal Cardiovascular Disease Severity Scale dem-
onstrated good inter- and intrarater reliability among
experienced fetal cardiologists. It therefore is a valid tool
for standardization of prenatal prognostic assessment of
CHD severity across institutions. It also can be used at
different points in time throughout gestation as a marker of
disease evolution. This scale can be used as a standard
component of data collection for research and has appli-
cations for parental counseling and transition of care during
delivery and after birth. Further evaluation of this scale
Pediatr Cardiol (2014) 35:1174–1180 1179
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may be applied prospectively to patients with CHD diag-
noses made in fetal life and validated on the basis of actual
outcomes, including number of interventions and quality-
of-life measures.
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